Clinical Trial

Bioequivalence Study of Valsatril Tablet Versus Entresto® Sacubitril/Valsartan 24/26 mg Tablet.

Name: Bioequivalence Study of Valsatril Tablet Versus Entresto® Sacubitril/Valsartan 24/26 mg Tablet. — clinical trial record (NCT07746908)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: (BABE)

Completed Phase 1

View on ClinicalTrials.gov →

Summary

This study is to evaluate the bioequivalence of Valsatril (Sacubitril/Valsartan) tablet 50 mg versus Entresto 50 mg tablet in healthy Pakistani volunteers under Fasting condition.

Trial Details

NCT Number	NCT07746908
Lead Sponsor	Center for Bioequivalence Studies and Clinical Research Collaborators: SAMI Pharmaceuticals (Pvt.) Ltd.
Conditions	Healthy Participants
Enrollment	60 participants
Start Date	2025-02-06
Primary Completion	2025-07-18 (estimated)
Study Completion	2025-07-18 (estimated)
Updated on ClinicalTrials.gov	2026-08-10